CytRx (CYTR) – Business Wire
-
LadRx Corporation Announces OTCQB Ticker Change to LADX
-
CytRx Corporation Relaunches as LadRx Corporation
-
European Patent Office Awards CytRx Key Patent
-
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
-
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
-
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
-
CytRx Partners with Oncology Development Expert to Advance LADR Platform
-
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
-
CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates
-
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
-
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
-
CytRx to Hold Town Hall for Stockholders on Thursday, January 20th
-
CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference
-
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer
-
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer
-
CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
-
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
-
CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
-
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C
-
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
-
CytRx to Present at Upcoming Virtual LD Micro Conference
-
CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
-
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
-
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
-
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
-
CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor
-
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor
-
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C
-
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C
-
CytRx to Present at Upcoming Investor Conferences
-
CytRx Comments on Quarterly Results and Year-to-Date Progress
-
CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
-
CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis
-
CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress
-
CytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
-
CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
-
CytRx to Participate in Upcoming Investor Conferences
-
CytRx is Added to the LD Micro Index
-
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients
-
CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C
-
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
-
CytRx Announces Orphazyme’s U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
-
CytRx Comments on Quarterly Results and Recent Strategic Progress
-
CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
-
CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol
-
CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment
-
CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer
-
CytRx Issues Statement Regarding Orphazyme’s Global Offering
-
CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C
Back to CYTR Stock Lookup
